UK Markets closed

Frequency Therapeutics, Inc. (FREQ)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
10.14+0.17 (+1.71%)
At close: 4:00PM EDT
9.90 -0.24 (-2.37%)
After hours: 05:03PM EDT

Frequency Therapeutics, Inc.

19 Presidential Way
2nd Floor
Woburn, MA 01801
United States
866 389 1970

Full-time employees83

Key executives

NameTitlePayExercisedYear born
Mr. David L. LucchinoCo-Founder, Pres, CEO & Director850.67kN/A1969
Dr. Christopher R. LooseCo­-Founder & Chief Scientific Officer616.44kN/A1981
Dr. Carl P. LeBelChief Devel. Officer611.62kN/A1959
Mr. William J. McLeanCo-­Founder and VP of Biology & Regenerative MedicineN/AN/AN/A
Mr. Peter P. PfreundschuhChief Financial OfficerN/AN/A1969
Mr. Richard J. MitranoVP of Fin. & OperationsN/AN/A1970
Dr. Jeff HrkachSr. VP of Technology Devel.N/AN/A1966
Mr. Michael D. Bookman J.D.Gen. Counsel & Sec.N/AN/A1987
Ms. Wendy S. ArnoldChief People OfficerN/AN/A1972
Dr. Dana C. HiltChief Medical OfficerN/AN/A1953
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on harnessing the body's innate biology to repair or reverse damage caused by a range of degenerative diseases. Its Progenitor Cell Activation approach, uses combinations of small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. Frequency Therapeutics, Inc. has a licencse and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, Mass General Brigham, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. The company was incorporated in 2014 and is headquartered in Woburn, Massachusetts.

Corporate governance

Frequency Therapeutics, Inc.’s ISS governance QualityScore as of 30 April 2021 is 8. The pillar scores are Audit: 1; Board: 8; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.